Q: What is the appropriate initial dose of corticosteroids to treat giant cell arteritis?

Cleveland Clinic Journal of Medicine

Volumn 67, Issue 8, 2000, Pages 546-548

  Wilke, W S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PREDNISOLONE; PREDNISONE; GLUCOCORTICOID;

BLINDNESS; CORTICOSTEROID THERAPY; DOSE RESPONSE; GIANT CELL ARTERITIS; HUMAN; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; NOTE; SIDE EFFECT; STROKE; ARTICLE; TEMPORAL ARTERITIS;

GLUCOCORTICOIDS; HUMANS; PREDNISONE; TEMPORAL ARTERITIS;

EID: 0033624160     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.67.8.546     Document Type: Note

References (11)

1. Analysis of steroid-related complications and mortality in temporal arteritis: A 15-year survey of 43 patients
2. Efficacy and adverse affects of different corticosteroid dose regimens in temporal arteritis: A retrospective study
3. Excess mortality in giant cell arteritis
4. Prognosis in giant cell arteritis
5. Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy
6. Iatrogenic morbidity accompanying suppression of temporal arteritis by adrenal corticosteroids
7. Treatment of corticosteroid-resistant giant cell arteritis
8. Polymyalgia rheumatica and corticosteroids: How much for how long?
9. Prevention of blindness in giant cell arteritis by corticosteroid treatment
10. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months
11. Long-term therapy in polymyalgia rheumatica: Effects of co-existent temporal arteritis